ProCE Banner Activity

CE / CME

Advancing Inflammatory Bowel Disease Management With Precision Medicine and Emerging Data

Text Module

This text module covers the current prevalence and impact of inflammatory bowel disease (IBD), how to integrate treat to target into one’s practice, and data on several emerging TL1A inhibitors and the promise they pose in transforming the IBD treatment landscape.

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: May 08, 2025

Expiration: May 07, 2026

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with the American Gastroenterological Association (AGA)

ProCE Banner

Supporters

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Merck & Co., Inc., Rahway, NJ, USA

Partners

AGA

ProCE Banner

Target Audience

The activity is intended for physicians, including residents and fellows, nurse practitioners, and physician associates practicing in gastroenterology. 

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners on implementation of the most recent clinical evidence, novel biomarkers, and emerging therapies with companion diagnostics in the evolving IBD treatment landscape to optimize and individualize patient care when available.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Detail available and emerging biomarkers and diagnostics informing treatment decisions in IBD

  • Incorporate available biomarkers appropriately into clinical practice based on guideline recommendations and expert consensus

  • Evaluate evidence for the utility of TL1A blockade in IBD treatment

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Jordan E. Axelrad, MD, MPH, FACG: consultant/advisor/speaker: AbbVie, Abviax, Adiso, bioMérieux, Bristol Myers Squibb, Celltrion, Ferring, Fresenius, Janssen, Merck, Pfizer, Vedanta; researcher: BioFire Diagnostics, Genentech, Janssen.

The planners and content peer reviewers from Clinical Care Options, LLC and the American Gastroenterological Association (AGA) do not have any relevant financial relationships to disclose. 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 08, 2025, through May 07, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

Physician Associate Continuing Medical Education

AAPA CME Accreditation - AAPA

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until May 07, 2026. PAs should only claim credit commensurate with the extent of their participation.

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.